CASPER MARC N 4

What Happened

• Marc N. Casper, Chairman & CEO (also a director) of Thermo Fisher Scientific (TMO), exercised 4,000 stock options on March 5, 2026 (exercise price $309.63; cash paid $1,238,520) and sold 4,000 shares in multiple open-market transactions the same day for aggregate proceeds of $2,059,261 (approx. $514.82/share average). The Form 4 also reports a related derivative disposition of 4,000 shares at $0.00 (reported as a derivative transaction).
• These actions are reporting sales (S) and option exercises (M); selling the shares after exercising is common and does not necessarily indicate a change in view on the company.

Key Details

• Transaction date: March 5, 2026; Form 4 filed March 9, 2026 (timely).
• Exercise: 4,000 shares acquired at $309.63 each (total $1,238,520).
• Sales: 4,000 shares sold across multiple trades for total proceeds $2,059,261 (weighted-average ≈ $514.82/share); individual sale price ranges are provided in the filing footnotes (see below).
• Shares owned after transaction: Not specified in the summarized data on this notice.
• Notable footnotes: Transactions were effected under a Rule 10b5-1 trading plan adopted November 11, 2025 (F1). Several weighted-average price footnotes list the price ranges for groups of trades (F2–F13). The filing also includes disclaimers regarding indirect beneficial ownership (F14, F15).
• Transaction codes: M = option exercise/convert; S = open-market sale.

Context

• This appears to be a routine exercise-and-sell sequence (exercise of vested options followed by market sales). The filing shows the option exercise and same-day sales; one line reports a derivative disposition at $0.00 consistent with option conversion/settlement reporting practices.
• Because the trades were made under a pre-existing Rule 10b5-1 plan, the trades were preauthorized and executed according to the plan’s terms (which can limit inference about timing or intent).